NASDAQ:RCM R1 RCM (RCM) Stock Price, News & Analysis → Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad) Free RCM Stock Alerts $11.99 -0.03 (-0.25%) (As of 04:00 PM ET) Add Compare Share Share Today's Range$11.82▼$12.0650-Day Range$10.45▼$14.5852-Week Range$8.87▼$18.70Volume1.95 million shsAverage Volume3.75 million shsMarket Capitalization$5.04 billionP/E RatioN/ADividend YieldN/APrice Target$16.87 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get R1 RCM alerts: Email Address R1 RCM MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.62 Rating ScoreUpside/Downside40.7% Upside$16.87 Price TargetShort InterestHealthy7.95% of Float Sold ShortDividend StrengthN/ASustainability-1.33Upright™ Environmental ScoreNews Sentiment0.46Based on 3 Articles This WeekInsider TradingSelling Shares$143,959 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.05) to $0.15 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.55 out of 5 starsBusiness Services Sector29th out of 305 stocksManagement Services Industry1st out of 5 stocks 4.3 Analyst's Opinion Consensus RatingR1 RCM has received a consensus rating of Moderate Buy. The company's average rating score is 2.62, and is based on 8 buy ratings, 5 hold ratings, and no sell ratings.Amount of Analyst CoverageR1 RCM has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted7.95% of the float of R1 RCM has been sold short.Short Interest Ratio / Days to CoverR1 RCM has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in R1 RCM has recently decreased by 3.86%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldR1 RCM does not currently pay a dividend.Dividend GrowthR1 RCM does not have a long track record of dividend growth. Previous Next 3.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreR1 RCM has received a 45.11% net impact score from Upright. R1 Rcm seems to create the most significant positive value in categories "Jobs", "Taxes", and "Physical diseases". The positive contribution in the "Physical diseases" impact category is mostly driven by its "Documentation software for clinicians", "Personal health record software", and "Hospital cost management software" products. See details.Environmental SustainabilityThe Environmental Impact score for R1 RCM is -1.33. Previous Next 1.4 News and Social Media Coverage News SentimentR1 RCM has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Business Services companies.News Coverage This WeekMarketBeat has tracked 3 news articles for R1 RCM this week, compared to 5 articles on an average week.Search InterestOnly 2 people have searched for RCM on MarketBeat in the last 30 days. This is a decrease of -87% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added R1 RCM to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, R1 RCM insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $143,959.00 in company stock.Percentage Held by Insiders37.00% of the stock of R1 RCM is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.10% of the stock of R1 RCM is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for R1 RCM are expected to grow in the coming year, from ($0.05) to $0.15 per share.Price to Book Value per Share RatioR1 RCM has a P/B Ratio of 1.83. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsTiny Biotech Stock Wins $75 Billion PatentA little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.Find out more here >>> About R1 RCM Stock (NASDAQ:RCM)R1 RCM Inc. provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers. The company also offers modular solutions, including functional partnership, an outsourcing solutions for improvements across targeted revenue cycle areas for hospital and physician group customers; revenue recovery, to fast-track payer and patient cash collections; revenue optimization, a solution to uncover missed or underreported revenue; clinical integrity, used to improve documentation and coding accuracy to maximize earned revenue for the services provided; and regulatory navigation, a compliance-first solutions for government reimbursement accuracy, pharmacy savings, and compliance. The company was incorporated in 2003 and is headquartered in Murray, Utah.Read More RCM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RCM Stock News HeadlinesApril 18, 2024 | bbc.co.ukSit Down Stand Up Olympian SpecialApril 12, 2024 | americanbankingnews.comR1 RCM (NASDAQ:RCM) Rating Reiterated by KeyCorpApril 19, 2024 | Behind the Markets (Ad)Forget NVIDIA, buy this $2 AI stock now…This company is at the center of a trillion-dollar industry, fighting for a piece of a massive $20 billion pentagon contract.April 11, 2024 | americanbankingnews.comR1 RCM (NASDAQ:RCM) Receives Overweight Rating from Cantor FitzgeraldApril 10, 2024 | americanbankingnews.comR1 RCM Inc. (NASDAQ:RCM) Given Average Rating of "Moderate Buy" by BrokeragesApril 9, 2024 | fxstreet.comEUR/USD holds above 1.0860, eyes on US CPI, ECB rate decisionApril 8, 2024 | axios.comVista takes Model N private for $1.25BApril 4, 2024 | finance.yahoo.comInbox Health Announces Appointment of Kent Ivanoff to Board of DirectorsApril 19, 2024 | Behind the Markets (Ad)Forget NVIDIA, buy this $2 AI stock now…This company is at the center of a trillion-dollar industry, fighting for a piece of a massive $20 billion pentagon contract.April 3, 2024 | finance.yahoo.comCapstreet-backed Surgical Notes Names Dominic Brignola as Chief Financial OfficerApril 1, 2024 | globenewswire.comR1 RCM to Release First Quarter 2024 Results on May 8, 2024April 1, 2024 | markets.businessinsider.comTruist Financial Reaffirms Their Hold Rating on R1 RCM (RCM)March 27, 2024 | globenewswire.comR1 Releases Fourth Annual Environmental, Social and Governance (ESG) ReportMarch 20, 2024 | markets.businessinsider.comBuy Rating Affirmed for R1 RCM Amid Strong Fundamentals and Prospective AcquisitionMarch 20, 2024 | msn.comR1 RCM pushes sales process forward, hiring bankersMarch 20, 2024 | msn.comR1 RCM gains amid Citi upgrade as deal still likely to happenMarch 20, 2024 | markets.businessinsider.comAnalyst Scoreboard: 12 Ratings For R1 RCMMarch 19, 2024 | wsj.comR1 RCM Tells Two Top Holders to End Buyout TalksMarch 19, 2024 | msn.comR1 RCM demands that New Mountain Capital & TCP-ASC talks must ceaseMarch 15, 2024 | finance.yahoo.comRCM Apr 2024 20.000 callMarch 12, 2024 | markets.businessinsider.comHold Rating on R1 RCM Amid Acquisition Talks and Valuation ConsiderationsMarch 11, 2024 | markets.businessinsider.comR1 RCM Announces Formation Of Special Committee To Evaluate Strategic AlternativesMarch 11, 2024 | msn.comR1 RCM forms special committee to evaluate options after New Mountain's offerMarch 11, 2024 | markets.businessinsider.comR1 RCM Poised for Growth: Outperform Rating and $17 Target Justified by Strong LBO Potential and Historical MultiplesMarch 11, 2024 | marketwatch.comR1 RCM to Explore Strategic Options After New Mountain ApproachMarch 11, 2024 | finance.yahoo.comR1 RCM Forms Special Committee to Evaluate Strategic AlternativesMarch 6, 2024 | msn.comTruist Securities Downgrades R1 RCM (RCM)See More Headlines Receive RCM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for R1 RCM and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/16/2023Today4/19/2024Next Earnings (Confirmed)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorBusiness Services Industry Management services Sub-IndustryHealth Care Services Current SymbolNASDAQ:RCM Previous SymbolNYSE:RCM CUSIP00438V10 CIK1472595 Webwww.r1rcm.com Phone(312) 324-7820Fax302-655-5049Employees30,000Year Founded2003Price Target and Rating Average Stock Price Target$16.87 High Stock Price Target$22.00 Low Stock Price Target$11.00 Potential Upside/Downside+42.5%Consensus RatingModerate Buy Rating Score (0-4)2.62 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$3.30 million Net Margins0.15% Pretax Margin0.93% Return on Equity0.12% Return on Assets0.07% Debt Debt-to-Equity Ratio0.57 Current Ratio1.83 Quick Ratio1.83 Sales & Book Value Annual Sales$2.25 billion Price / Sales2.21 Cash Flow$0.67 per share Price / Cash Flow17.73 Book Value$6.56 per share Price / Book1.80Miscellaneous Outstanding Shares420,730,000Free Float265,060,000Market Cap$4.98 billion OptionableOptionable Beta0.78 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Lee Rivas (Age 49)CEO & Director Comp: $1.12MMr. John M. Sparby (Age 48)President Comp: $656.99kMs. Jennifer Williams (Age 47)Executive VP, CFO & Treasurer Ms. Pamela L. Spikner (Age 47)Principal Accounting Officer & Chief Accounting Officer Evan Smith C.F.A.Senior Vice President of Finance & Investor RelationsMr. Corey PermanExecutive Vice President of Compliance & RiskMr. Sean RadcliffeExecutive VP, General Counsel & Corporate SecretaryMs. Kate SandersonExecutive VP & Chief Human Resources OfficerMr. David StrickleExecutive Vice President of IntegrationMr. Kyle A. Hicok (Age 44)Executive VP & Chief Commercial Officer More ExecutivesKey CompetitorsMaximusNYSE:MMSShift4 PaymentsNYSE:FOURExlServiceNASDAQ:EXLSSPX TechnologiesNYSE:SPXCTerminix GlobalNYSE:TMXView All CompetitorsInsiders & InstitutionsState of Michigan Retirement SystemBought 1,200 shares on 4/18/2024Ownership: 0.012%Oak Thistle LLCBought 20,563 shares on 4/18/2024Ownership: 0.005%Cannon Global Investment Management LLCBought 18,200 shares on 4/17/2024Ownership: 0.004%PNC Financial Services Group Inc.Bought 908 shares on 3/22/2024Ownership: 0.005%Vanguard Group Inc.Sold 2,744,298 shares on 3/11/2024Ownership: 3.616%View All Insider TransactionsView All Institutional Transactions RCM Stock Analysis - Frequently Asked Questions Should I buy or sell R1 RCM stock right now? 13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for R1 RCM in the last twelve months. There are currently 5 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RCM shares. View RCM analyst ratings or view top-rated stocks. What is R1 RCM's stock price target for 2024? 13 equities research analysts have issued 12 month target prices for R1 RCM's stock. Their RCM share price targets range from $11.00 to $22.00. On average, they anticipate the company's share price to reach $16.87 in the next twelve months. This suggests a possible upside of 40.7% from the stock's current price. View analysts price targets for RCM or view top-rated stocks among Wall Street analysts. How have RCM shares performed in 2024? R1 RCM's stock was trading at $10.57 on January 1st, 2024. Since then, RCM stock has increased by 13.4% and is now trading at $11.99. View the best growth stocks for 2024 here. When is R1 RCM's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our RCM earnings forecast. How can I listen to R1 RCM's earnings call? R1 RCM will be holding an earnings conference call on Wednesday, May 8th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link. How were R1 RCM's earnings last quarter? R1 RCM Inc. (NASDAQ:RCM) posted its quarterly earnings results on Thursday, February, 16th. The healthcare provider reported ($0.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.03) by $0.06. The healthcare provider had revenue of $532.80 million for the quarter, compared to analysts' expectations of $519.28 million. R1 RCM had a trailing twelve-month return on equity of 0.12% and a net margin of 0.15%. R1 RCM's revenue was up 33.6% on a year-over-year basis. During the same period last year, the company posted $0.11 EPS. What ETFs hold R1 RCM's stock? ETFs with the largest weight of R1 RCM (NASDAQ:RCM) stock in their portfolio include Global X Telemedicine & Digital Health ETF (EDOC), Fidelity Digital Health ETF (FDHT) and SPDR S&P Health Care Services ETF (XHS).iShares U.S. Healthcare Providers ETF (IHF). What guidance has R1 RCM issued on next quarter's earnings? R1 RCM updated its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $2.6 billion-$2.7 billion, compared to the consensus revenue estimate of $2.7 billion. What is Joseph Flanagan's approval rating as R1 RCM's CEO? 253 employees have rated R1 RCM Chief Executive Officer Joseph Flanagan on Glassdoor.com. Joseph Flanagan has an approval rating of 70% among the company's employees. What other stocks do shareholders of R1 RCM own? Based on aggregate information from My MarketBeat watchlists, some companies that other R1 RCM investors own include NVIDIA (NVDA), JD.com (JD), Baozun (BZUN), Inseego (INSG), BioXcel Therapeutics (BTAI), Marvell Technology (MRVL), Akoustis Technologies (AKTS), Alibaba Group (BABA), Bilibili (BILI) and Model N (MODN). Who are R1 RCM's major shareholders? R1 RCM's stock is owned by a number of institutional and retail investors. Top institutional shareholders include State of Michigan Retirement System (0.01%), Oak Thistle LLC (0.00%) and Cannon Global Investment Management LLC (0.00%). Insiders that own company stock include Achi Series Lllp Tcp-Asc, Alex Mandl, John B Henneman III, John M Sparby, Joseph Gerard Flanagan, Lee Rivas and Richard B Jr Evans. View institutional ownership trends. How do I buy shares of R1 RCM? Shares of RCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does R1 RCM have any subsidiaries? The following companies are subsidiares of R1 RCM: Accretive Health Mauritius Inc., Cerner RevWorks, Clearsight Intermediate Holdings Inc., Cloudmed, Flare Capital Partners Investment Company, Intermedix, Intermedix ARM LLC, Intermedix Corporation, Intermedix Holdings Inc., Intermedix Lietuva UAB, Intermedix Midco Inc., Intermedix Office Based LLC, Intermedix Staffing Inc., Medical Consultants Inc., Practice Support Resources LLC, Project Links Parent Inc., Project Roadrunner Merger Sub Inc., Project Roadrunner Parent Inc., R1 RCM Global Private Limited, R1 RCM India Private Limited, Rover16 Inc., SCHEDULING.COM INC., SCI Solutions, Tonic Health LLC, VisitPay, cGate Health Inc., and iVinci Partners LLC.Read More This page (NASDAQ:RCM) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe “Perfect Storm” for GoldGold Safe ExchangeTiny Biotech Stock Wins $75 Billion PatentBehind the MarketsBiden’s $374B Giveaway Into This SectorDTIHe Is Giving Away BitcoinCrypto Swap ProfitsThe "Smart Money" Is Ready for May 1st Are You?Stansberry ResearchThe #1 Crypto for 2024InvestorPlaceYour Money is Not SafeAmerican Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding R1 RCM Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.